

SYNTHETIC COPPER-CONTAINING PARTICLES ENHANCE ALLERGIC AIRWAY RESPONSES IN MICE. *SH Gavett, MI Gilmour, and N Haykal-Coates.*

National Health and Environ Effects Research Lab, USEPA, Res Triangle Park, NC USA

Respiratory morbidity and mortality associated with increases in ambient levels of particulate matter (PM) may be dependent on particle elemental composition. Particle-associated metals such as copper may catalyze formation of reactive oxygen species leading to inflammation and lung injury. We studied the ability of chemically defined synthetic particles to enhance allergic inflammation and airway hyperresponsiveness in ovalbumin (OVA)-allergic mice. Particles (<2 µm) were synthesized with a base of 50% carbon, 15% NH₄Cl, and 30% Na₂SO₄. Control carbon (C) particles contained an extra 5% carbon, while carbon-zinc (CZn) or carbon-copper (CCu) particles contained 5% zinc sulfate or copper sulfate (2.0% Zn(II) or Cu(II) metal; 0.31 mmol/gm particle). Female BALB/cJ mice were sensitized i.p. with OVA in aluminum hydroxide adjuvant or were administered adjuvant only; all mice were challenged with OVA aerosol 14 or 15 d later. One hour after challenge mice were intratracheally instilled with saline, C, CZn, or CCu in saline vehicle (2 mg/kg; ~40 µg). Both nonallergic and allergic CCu-exposed mice were hyperresponsive to methacholine aerosol challenge (Buxco; 4-32 mg/ml) 1 day (~4-fold increase) and 8 days (~2-fold increase) after exposure compared with all other groups. Bronchoalveolar lavage (BAL) fluid eosinophils, neutrophils, lactate dehydrogenase, protein, albumin, N-acetyl-β-D-glucosaminidase, interleukins-4, -5, -13, interferon-γ, and tumor necrosis factor-α were all significantly increased in CCu-exposed mice compared with saline-, C-, or CZn-exposed groups. These data show that PM-associated copper enhances allergic inflammation and airway hyperresponsiveness in mice, and are consistent with recent studies (Dye, *Env Health Perspect* 2001; Ghio, *AJRCCM* 2001) relating toxicological effects with epidemiological findings of health effects of PM containing high concentrations of copper.

This abstract is funded by: U.S. EPA. (This abstract does not reflect EPA policy.)

MECHANISMS OF Zn-INDUCED SIGNAL INITIATION THROUGH THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)

James M. Samet, Lee M. Graves§ and Weidong Wu§.* *Human Studies Division, NHEERL, ORD, Research Triangle Park, NC 27711, and § Center for Environmental Medicine, University of North Carolina, Chapel Hill, NC 27599.

Zn is a ubiquitous component of ambient air particulate matter and an occupational toxicant. We have shown that Zn ions induce EGFR activation and signaling. To elucidate the mechanism involved in Zn-induced activation of this receptor kinase, we studied EGFR dimerization, phosphorylation and kinase activity in A431 cells treated with ZnSO₄ and compared the effects to those induced by its ligand EGF. A431 extracts were incubated with 500 µM ZnSO₄ or 200 ng/ml EGF for 30 min, followed by treatment with a cross-linking agent (BS³) and Western blotting. As expected, EGF induced pronounced dimerization of EGFR molecules. However, Zn treatment failed to induce detectable EGFR dimerization. Analyses of intact A431 cells treated in a similar manner confirmed that Zn does not induce dimerization of EGFR. Western blotting using phospho-specific antibodies showed that Zn induced phosphorylation of EGFR at tyrosines 845, 1068 and 1173, a pattern identical to that produced by EGF treatment. The EGFR kinase inhibitor PD153035 effectively ablated all phosphorylation induced by EGF but none caused by Zn treatment of A431 cells. Similarly, PD153035 abolished EGF-induced phosphorylation of the EGFR substrate cbl, while it had no effect on levels of phospho-cbl that resulted from Zn treatment. Together, these results confirm that Zn ions effectively activate EGFR and show that the mechanism includes EGFR phosphorylation but does not involve EGFR dimerization or EGFR kinase activation, suggesting that Zn induces a transactivation of EGFR in A431 cells. These findings may provide a mechanistic basis for the adverse effects of Zn inhalation. This abstract of a proposed presentation does not necessarily reflect EPA policy.

This abstract is funded by:

THE EFFECTS OF SINGLE AND SERIAL ZINC OXIDE EXPOSURES ON AIRWAY INFLAMMATION IN HEALTHY HUMANS

K Reintjes, A Witten, M Ariomandi, J Balmes, P Blanc¹, C Solomon Lung Biology Center; ¹Department of Medicine, University of California, San Francisco, CA, U.S.A.

A single exposure to zinc oxide (ZnO) results in an increase in inflammatory cells and cytokines. Serial exposures to ZnO can decrease this inflammatory response. This experiment was designed to test the hypothesis that exposure to ZnO on two consecutive occasions would decrease both the cellular and cytokine responses compared to one exposure. Utilizing a repeated measure, randomized, single-blind design, 6 healthy subjects (4 females; age range 26-53 yr; methacholine PC₂₀ > 10 mg/ml) were exposed for 30 min, at rest, to: 1) filtered-air (FA); 2) ZnO on one occasion (ZnO-1; conc: 10 mg/m³); 3) ZnO on two consecutive occasions (ZnO-2; conc: 10 mg/m³). Sputum induction (3% saline, t=20 min) was performed 65 h pre- and 6 h post-exposure. Conditions were compared using the post minus pre delta value. In ZnO-1, compared to FA, there was a significant (P<0.05) increase in the total leukocyte concentration (median; 25-75% range: 16.6; 7.5-23.0 vs -0.3; 0.3-0.8 x 10⁶ cells/ml), and TNFα (1.4; 0.6-6.5 vs 0.6; -0.1-1.8 pg/ml). In ZnO-2, compared to FA, there was a significant increase in TNFα (2.8; 1.0-7.0 vs 0.6; -0.1-1.8 pg/ml). For all three conditions there were no other differences in total leukocyte concentration, or macrophage, neutrophil, lymphocyte, or eosinophil differential percent, or in total protein, TNFα, or IL-8. These results indicate that serial exposure to ZnO does not result in the increase in leukocytes observed for a single exposure, but that serial exposure does not change the TNFα response.

This abstract is funded by: COEH/NIOSH: T421/CCT910427

QUANTITATIVE TRAIT LOCUS ANALYSIS OF THE DEVELOPMENT OF PULMONARY TOLERANCE TO INHALED ZINC OXIDE. *SC Wesselkamper¹, LC Chen¹, SR Kleberger², M-S Tang¹, and T Gordon¹.* ¹Dept. of Env. Med., NYU School of Med., Tuxedo, NY; ²Dept. of Env. Health Sci., Johns Hopkins Univ., Baltimore MD.

As a result of repeated exposure to inhaled toxic agents in different occupations and environmental settings, individuals may develop tolerance to adverse health effects. Thus, the identification of innate and extrinsic factors that influence the ability to develop tolerance is a significant issue. Among inbred strains of mice, the BALB/cByJ (CBy) strain exhibits greater pulmonary tolerance to PMN and protein levels in lavage fluid than DBA/2J (D2) following 5 successive exposures (5X) to 1.0 mg/m³ ZnO. A genome-wide screen using 298 F2 mice (CByD2F1xCByD2F1) that were phenotyped for the development of pulmonary tolerance following 5X ZnO exposure identified a significant quantitative trait locus (QTL) for the BAL protein phenotype on chromosome 1. An excellent candidate gene within this QTL is the toll-like receptor 5 gene (*Tlr5*) which is part of a family of toll-like receptor genes that are important in the induction of the innate immune response. Affymetrix GeneChip oligonucleotide microarray analyses were conducted to examine ZnO-induced expression of genes up- and downstream in the toll-like receptor signaling pathway and identify candidate genes present in other chromosomal regions of interest. Interestingly, the toll-like receptor 4 gene (*Tlr4*) has been shown to be a strong candidate susceptibility gene for ozone-induced increases in the BAL protein phenotype in inbred mice. Taken together, these studies suggest that the toll-like receptor pathway may play a role in genetic regulation of the pulmonary response to inhaled particles and gases.

EPA, NIOSH

This abstract is funded by:

VANADYL SULFATE INDUCES PULMONARY VASOCONSTRICTION BY DECREASING NITRIC OXIDE (NO) BIOAVAILABILITY.

Y.C. Huang, L. Dailey, I. Demchenko, J.D. Carter. ORD, US EPA, RTP, NC and Duke University Medical Center, Durham, NC.

Exposure to particulate matter (PM) has been associated with acute cardiovascular adverse events, but biologically relevant mechanisms are unclear. PM of combustion sources contain redox-active metals such as vanadium (V) and copper, which may alter vasoreactivity. We showed previously that intratracheal instillation of a V-rich PM dust, residual oil fly ash, produced pulmonary vasoconstriction that could be attributed in part to V permeating into the pulmonary circulation. The present study investigated if the V-induced pulmonary vasoconstriction was related to decreased NO bioavailability in isolated perfused lungs (IPL) and pulmonary artery (PA) rings. Vanadyl sulfate (0.5-50 µM) produced a dose-dependent increase in PA pressure in IPL, and inhibited acetylcholine-mediated vasodilation in pre-constricted PA rings. V inhibited accumulation of nitrite/nitrate and free nitrotyrosine in the perfusate, and decreased nitrotyrosinated α-tubulin in the lung. V-induced pulmonary vasoconstriction was attenuated by SOD, PAPANONate (an NO donor) and DPI (an NADH oxidoreductase inhibitor), but not by catalase, genistein or PD153035 (an epidermal growth factor receptor antagonist). Copper sulfate, but not zinc sulfate, causes similar pulmonary vasoconstriction. These results indicate that V-induced pulmonary vasoconstriction may be mediated in part by NADH oxidoreductase-derived superoxide, which may act as a vasoconstrictor or react with NO resulting in the loss of NO-mediated vasodilation. The results raise the hypothesis that exposure to PM containing high levels of certain metals may produce adverse pulmonary vasoconstriction causing acute decompensation of the heart in patients with pre-existing cardiopulmonary diseases. (This abstract does not reflect EPA policy).

This abstract is funded by:

RESIDUAL OIL FLY ASH (ROFA)-INDUCED LUNG INJURY IN MICE:

ROLE OF TOLL-LIKE RECEPTOR 4 (TLR4) SIGNALING. *Hye-Youn Cho¹,*

Anne E. Jedlicka¹, Liu-Yi Zhang¹, Robert Clarke², and Steven R. Kleberger¹.

¹Dept. of Environmental Health Sciences, Johns Hopkins University, Baltimore, MD and

²Advanced Inhalation Research, Inc., Cambridge MA.

We previously demonstrated significant inter-strain (genetic) variation in ROFA-induced lung inflammation and hyperpermeability. A significant difference in the hyperpermeability response between susceptible C3H/HeO_uJ (O_uJ) and resistant C3H/HeJ (HeJ) mice was particularly interesting as they differ only at a polymorphism in the coding region of the gene for Toll-like receptor 4 (*Tlr4*). *Tlr4* has an important role in innate immunity and responsiveness to bacterial endotoxin and the oxidant ozone. The objective of this study was to characterize the *Tlr4*-mediated signaling pathway in HeJ and O_uJ mice following ROFA challenge and to identify candidate effector genes that mediate differential responses in these strains. Marked upregulation of lung *Tlr4* message level was observed in O_uJ mice but not in HeJ mice following ROFA challenge. Basal and ROFA-induced lung TLR4 protein levels were higher in O_uJ mice than in HeJ mice. Greater activation of the TLR4 downstream signal molecules MyD88, TRAF6, IRAK-1, IκB-α, and NF-κB in O_uJ mice compared to HeJ mice supported a role for *Tlr4* in hyperresponsiveness to ROFA in murine lungs. Microarray cytokine profile analysis of ROFA-exposed lungs indicated several inflammatory cytokines, including interleukin (IL)-1β, were differentially regulated in HeJ and O_uJ mice. Results suggest an important role of genetic background in response to ROFA exposure, and indicate innate immune defense mechanisms through TLR4 are important determinants of differential susceptibility.

NIH ES-09609, R01 HL-57142; EPA R-826724

This abstract is funded by:

AMERICAN JOURNAL OF

Respiratory and Critical Care Medicine

ISSN 1073-449X

SUPPLEMENT

April 2002

Volume 165

Number 8

AMERICAN THORACIC SOCIETY

ABSTRACTS

2002 International Conference

May 17–22, 2002 • Atlanta, Georgia

Contents	A3
Sunday, May 19	A11
Monday, May 20	A235
Tuesday, May 21	A453
Wednesday, May 22	A695
Index	A837
Late-Breaker Abstracts	B1

This special supplement of the *American Journal of Respiratory and Critical Care Medicine* contains abstracts of the scientific papers to be presented at the 2002 International Conference. The abstracts appear in order of presentation, from Sunday, May 19 through Wednesday, May 22 and are identified by session code numbers. To assist in planning a personal schedule for the Conference, the time and place of each presentation is also provided.

GMISP125 THE CDC GRANTS MANAGEMENT INFORMATION SYSTEM 06/17/03
GMISM035 GRANT AWARD RECORD 16:26
AH07AH00 (SCREEN NO.1)

AWARD NO.....: 910427 PROGRAM CODE.....: T42 AWARD DATE.: 05/20/1994
CRS EIN.: 1-946002123-A1 AWARD TYPE.....: G FED CAT NO.....: 93.263
CIO CODE.....: NIOSH OBJ CLASS.....: 41.21 PHS LIST NO: CL-009-G03
PROJ PER FROM: 07/01/1994 PROJ PER TO: 06/30/2007 ANNOUNCEMENT NO.: 02001
PREV AWARD NO: PROGRAM CATEGORY...: I5 FC CODE.....:

PROGRAM NAME: AUTHORIZATION: 42 USC 241 - P.L. 91-596
EDUCATION AND RESEARCH CENTER

GRANTEE NAME...: UNIVERSITY OF CALIFORNIA
BUSINESS OFFICE: SPONSORED PROJECTS OFFICE
STREET.....: 336 SPROUL HALL
CITY.....: BERKELEY
STATE: CA ZIP CODE: 94720-5940 PHONE:(510) 642-8109-

PROJ DIRECTOR..: ROBERT C. SPEAR, PH.D.
DEPARTMENT.....: CTR FOR OCC. & ENV. HEALTH
STREET.....: 140 WARREN HALL
CITY.....: BERKELEY
STATE: CA ZIP CODE: 94720-7360 PHONE:(510) 642-0761-

DISPLAY PF10-RETURN GRANT AWARD MENU PF16-MAIN MENU

IN: Cooperative - Agreement - T42 - CCT - 910427

GMISP125
GMISM037
AH07AH00

THE CDC GRANTS MANAGEMENT INFORMATION SYSTEM
GRANT AWARD RECORD
(SCREEN NO.3)

06/17/03
16:26

AWARD NO: 910427
ACTION TYPE...: 6

YEAR.....: 9
AMEND NO.: 1

FISCAL YEAR.....: 2002
ACTION DATE: 02/04/2003

APPROVED BUDGET (1): GRANT FUNDS ONLY (Y/N): Y
SALARIES WAGES.....: 177,793
FRINGE BENEFITS.....: 30,966
TOTAL PERSONNEL COSTS...: 208,759
CONSULTANT COSTS.....: 5,200
EQUIPMENT.....: 2,394
SUPPLIES.....: 13,495
TRAVEL.....: 21,950
OTHER.....: 37,500
CONTRACTUAL COSTS.....: 403,172
TRAINEE EXPENSES.....:
TRAINEE STIPENDS.....: 132,991
TRAINEE TUITION & FEES....: 67,510
TRAINEE TRAVEL.....: 2,500
TOTAL DIRECT COSTS (FA): 895,471

DISPLAY

PF10-RETURN GRANT AWARD MENU

PF16-MAIN MENU

GMISP125 THE CDC GRANTS MANAGEMENT INFORMATION SYSTEM 06/17/03
GMISM125 GRANT AWARD RECORD 16:26
AH07AH00 (SCREEN NO.4)

AWARD NO: 910427 YEAR.....: 9 FISCAL YEAR.....: 2002
ACTION TYPE...: 6 AMEND NO.: 1 ACTION DATE: 02/04/2003

APPROVED BUDGET (2):
INDIRECT COST RATE.....: 8.0000
INDIRECT COST RATE CODE.....: G
INDIRECT COSTS (FA).....: 33,793
SBIR FEE.....:
TOTAL APPROVED BUDGET.....: 929,264
NON FEDERAL SHARE.....:

AWARD COMPUTATION FOR GRANT:
FED SHARE/PHS ASSISTANCE.....: 929,264
UNOB FINANCIAL ASSISTANCE.....: 26,377
CUM PRIOR AWARD THIS BUD (FA): 902,887
AMOUNT THIS ACTION (FA).....:

DISPLAY PF10-RETURN GRANT AWARD MENU PF16-MAIN MENU

GMISP125
GMISM141
AH07AH00

THE CDC GRANTS MANAGEMENT INFORMATION SYSTEM
GRANT AWARD RECORD
(FSR)

06/17/03
16:26

AWARD NO: 910427 YEAR: 9
UNOBLIGATED AMOUNT: 26,377

UNOB YEAR FROM UNOB AMOUNT
8 26,377.00

PF10-RETURN GRANT AWARD MENU PF16-MAIN MENU

GMISP125
GMISM101
AH07AH00

THE CDC GRANTS MANAGEMENT INFORMATION SYSTEM
GRANT AWARD RECORD
(SCREEN NO.5)

06/17/03
16:26

AWARD NO: 910427

YEAR: 9

FISCAL YEAR: 2002

APPROVED DIRECT ASSISTANCE BUDGET:

PERSONAL SERVICE.....:
TRAVEL.....:
VACCINE.....:
OTHER.....:
OTHER DESCRIPTON:
TOTAL DIRECT COSTS (DA).....:
UNOB DIRECT ASSISTANCE.....:
CUM PRIOR AWARD THIS BUD (DA):
AMOUNT THIS ACTION (DA).....:

COMPETITIVE ACTION (Y/N): N

DISPLAY

PF10-RETURN GRANT AWARD MENU

PF16-MAIN MENU

GMISP125
GMISM110
AH07AH00

THE CDC GRANTS MANAGEMENT INFORMATION SYSTEM
GRANT AWARD RECORD
(SCREEN NO.6)

06/17/03
16:26

AWARD NO.:..... 910427 YEAR:..... 9 FISCAL YEAR:....: 2002

CAN AWARD DATE	ALLOW CODE	FY-CAN	AMT FIN	ASSIST	AMT DIR ASSIST
07/03/2002	11L18	02-9218877		827,887	
07/03/2002	11LY8	02-9278780		75,000	

-
-
-
-
-
-
-
-
-
-

DISPLAY

PF10-RETURN GRANT AWARD MENU

PF16-MAIN MENU

GMISP125
GMISM038
AH07AH00

THE CDC GRANTS MANAGEMENT INFORMATION SYSTEM
GRANT AWARD RECORD
(SCREEN NO.7)

06/17/03
16:26

AWARD NO.:..... 910427 YEAR:..... 9 FISCAL YEAR:.... 2002
BUD PER FROM: 07/01/2002 BUD PER TO: 06/30/2003 PROGRAM INCOME:.... B
PROJ PER FROM: 07/01/1994 PROJ PER TO: 06/30/2007

RECOMMENDED FUTURE SUPPORT:

YEAR	TOTAL DIRECT COST	YEAR	TOTAL DIRECT COST	YEAR	TOTAL DIRECT COST
10	1,007,530	11	1,062,478	12	753,274
13	796,473				

FREQ	REPORT	DUE DATE	REC DATE	LTR 1 DATE	LTR 2 DATE
	FSR	09/30/2003			
A	PRO REP1	09/30/2003			
	PRO REP2				
	PRO REP3				
	PRO REP4				
	PRO REP5				
	PRO REP6				
	PRO REP7				
	PRO REP8				

DISPLAY

PF10-RETURN GRANT AWARD MENU

PF16-MAIN MENU